Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL

(MedPage Today) -- The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news